Astellas Poland You were appointed general manager of Astellas Poland in early 2006, only a bit after Astellas Pharma Inc. was established, on April 1, 2005 through the merger of the mother companies Yamanouchi and Fujisawa. Could you describe to our readers the evolution of the affiliate since the merger? Astellas has…
Bristol-Myers Squibb France BMS recently announced divesting from their facilities in Epernon and Meymac but at the same time reinforcing manufacturing in Agen. Could you speak to strategy of this restructuring within France and what it means for the future? In the larger context of the industry, we are at a crossroads where…
Daiichi Sankyo Germany DAIICHI SANKYO in Germany, Austria and Switzerland DAIICHI SANKYO wants to be a Global Pharma Innovator with Germany at the center of this process on the European continent. An example of this development is your manufacturing facility in Pfaffenhofen, a basis to export to more than 50 countries. Can you…
AstraZeneca Poland You have been quite recently appointed at the head of the Polish affiliate of AstraZeneca. With which personal ambitions did you come and what was the mission you were given when you took office? I would not say that I have been given a mission, but that I have been…
Ipsen Brazil In a past interview, you said that Ipsen is different than the “Big Pharmas” who have entered Brazil by acquisition. You’ve taken a different tack since arriving as one of the newer international companies to Brazil, and you have been here since ground zero in 2007. What prompted that initial…
GlaxoSmithKline Colombia Michael Sean Reilly: General Manager for Pharmaceuticals Juan Carlos Berbessi: Medical Director Maria del Pilar Rubio: Medical Manager for Vaccines Gustavo Zapata: Finance Director Juan Pablo Restrepo: Legal Affairs Manager What is the strategic role and importance of Colombia within the larger global framework of GlaxoSmithKline (GSK)? Michael Sean Reilly:…
Novo Nordisk Brazil Diabetes affects an estimated 6 million Brazilians, a figure which is expected to double by 2025, in line with many other developing nations. Like many other “rich-country” diseases, there is a tendency for its sudden prevalence to result in less-than-adequate treatment profiles. What have you observed here in Brazil? The…
GSK Brazil You’ve made some bold moves in your career – from the head of vaccines in Latin America, followed by stints in Colombia, Puerto Rico, and finally Brazil. What brought you along that trajectory, and what have been some of the most important milestones since your arrival here in 2008? I…
Romanian Association of International Drug Manufacturers (ARPIM) While, today, you are in charge of voicing the concerns of the innovators in the country, let us first take a step back and see what attracted these companies to Romania in the first place. Can you tell our readers more about the key factors of attraction in that sense?…
Farmindustria & Laboratorio Volta As the CEO of Farmindustria since 1998, what would you say has been your recipe for the impressive success that the company has experienced, considering that Farmindustria represents 35% of all contract manufacturing activities in Chile? Our strongest key to success has certainly been the team that work’s here. Manufacturing…
Bausch & Lomb Poland BAUSCH + LOMB has over 150 years of heritage and has always been associated with optics and ophthalmology. Therefore the company has been able to build a very strong brand image throughout the years and is today recognized as the best in eye health. Would you say it is an…
OEP Philippines Mr. Chang, can you please give an overview of the establishment of OEP Philippines and the company’s current activities here? OEP Philippines started by acquiring the operations of Elan Pharma Phils, an Irish company. In 2003, when Elan Pharma decided to dispose of their subsidiary in the Philippines, Mr. Peter…
See our Cookie Privacy Policy Here